Drug Repurposing News



NuMedii, Inc. Announces New Partnership To Discover And Advance New Treatments For Idiopathic Pulmon

April 13th 2017, Posted by: Drug Repurposing Portal

NuMedii & Three Lakes Partners, LLC enter into a collaboration in the pursuit of identifying therapies for idiopathic pulmonary fibrosis (IPF) based on NuMedii's Big Data intelligence technology. NuMedii's CEO, Gini Deshpande says "This unique partnership between an AI drug discovery company and a patient-centric organization further builds on our work in inflammation and showcases our progress, particularly our development capabilities in rare disease."


News Methods Funding Collaborations

Paradigm pushes into drug repurposing

January 6th 2017, Posted by: Drug Repurposing Portal

The drug pentosan polysulfate sodium (PPS) is essentially an anti-inflammatory and an antihistamine with biological characteristics that make it ideally suited for treating hayfever and edema and viral arthritis. However, Paradigm Biopharmaceuticals is testing PPS for new indications and it has patent applications relating to the use of PPS in the treatment of Ross River virus and Chikungunya. Chief executive of Paradigm Biopharmaceuticals, Paul Rennie, said regulatory shifts would make it difficult for the large pharmaceutical companies to replicate massive profits and give smaller players an opportunity to find profits.


News Methods Funding Collaborations

IBM, Teva to Use A.I. for Drug Repurposing Program

October 26th 2016, Posted by: Drug Repurposing Portal

IBM's artificial intelligence program Watson is diving deeper into health care. The computing giant and Teva Pharmaceuticals announced on Wednesday that they were taking their ongoing health partnership into new territory. Both firms will work together on a chronic disease management system combining IBM's cognitive computing capabilities with Teva's therapeutic technology. This program would harness 6 billion data points along with cloud-connected drug delivery and app technology to help calculate the risk of potential health events like an asthma attack.


News Methods Funding Collaborations

Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection

August 29th 2016, Posted by: Drug Repurposing Portal

Research investigators from the Johns Hopkins University School of Medicine, the National Institutes of Health and Florida State University screened about 6000 compounds (in late clinical stage or approved for human use for various indications), identifying several compounds that might be able to cure Zika virus infections.


News Methods Funding Collaborations

PSR Orphan Experts, Raremark Announce Rare Disease Tieup

June 16th 2016, Posted by: Drug Repurposing Portal

The Netherlands-based orphan drug consulting and research company PSR Orphan Experts has signed a pact with Raremark, a new online service for families affected by rare disease, on a partnership designed to speed up the development of new treatments. London's Raremark will engage families in the clinical trial process, helping them understand what taking part in a study means, and keeping them informed while participating in one. Meanwhile PSR will provide strategic and operational consulting, in addition to its traditional CRO services.


News Methods Funding Collaborations

Ixaltis Gets Funds to Repurpose Drug

June 13th 2016, Posted by: Drug Repurposing Portal

Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm?s pipeline consists of three compounds licensed from Sanofi. The most advanced is litoxetine, a serotonin reuptake inhibitor and 5-HT3 receptor antagonist that Sanofi had studied as an antidepressant. Ixaltis will soon begin testing the compound in a Phase II trial for treating urinary incontinence.


News Methods Funding Collaborations

Astellas continues IT-enabled Drug Repurposing Deal Drive with Excelra hook-up

June 10th 2016, Posted by: Drug Repurposing Portal

Astellas Pharma has struck its third drug repurposing agreement of the past 6 months. The latest collaboration sees Astellas start working with Excelra, an Indian informatics company that has landed 8 similar deals on the strength of its drug repurposing database and accompanying algorithms. For Excelra, the deal with Astellas marks an advance in its attempts to establish itself as a standalone business.


News Methods Funding Collaborations

Excelra Expands Its Drug Repurposing Solutions Outreach in Europe through Collaboration with H.M. Pharma Consultancy

May 23rd 2016, Posted by: Drug Repurposing Portal

Excelra, Asia's leading knowledge Solutions Company, today announced its collaboration with H.M. Pharma Consultancy (HMPC), a life science consulting enterprise based in Austria, to jointly provide Drug repurposing services to Pharma and Biotech companies across Europe. Drug Repurposing at Excelra is driven by its proprietary platform called GRIP-Global Repurposing Integrated Platform. The platform uses unique algorithm driven techniques that allow you to expedite drug centric, disease centric and target centric repurposing of marketed and failed/shelved compounds.


News Methods Funding Collaborations

Melior Discovery Announces Spinout of Melior Pharmaceuticals II, LLC

May 10th 2016, Posted by: Drug Repurposing Portal

Melior Discovery, Inc., a leader in the area of drug repositioning, announced today that it has completed the formation of its second therapeutic area-focused pharmaceutical company, Melior Pharmaceuticals II, LLC. This will help build new collaborations with various partners, pool-in new investors and focus on the MLR-1019 asset to address the unmet need of Parkinson's disease. Operational efficiency-new investment-specialized team focused in the disease area is the new mantra.


News Methods Funding Collaborations

Recursion Pharmaceuticals Announces Research Agreement with Sanofi Genzyme

April 25th 2016, Posted by: Drug Repurposing Portal

Recursion Pharmaceuticals had announced a research agreement with Sanofi Genzyme, the specialty care global business unit of Sanofi, especially for rare diseases, to deploy its drug repurposing platform to identify new uses for Sanofi?s clinical stage molecules across dozens of genetic diseases.


News Methods Funding Collaborations

Cyclica and Cures Within Reach collaborate on finding potential Idiopathic Pulmonary Fibrosis therapy

April 4th 2016, Posted by: Drug Repurposing Portal

Idiopathic Pulmonary Fibrosis (IPF) is one of the focus areas for Cures Within Reach (CWR) and Cyclica, investiageted the repurposing candidates identified by CWR using its proteome wide docking platform. To idnetify additional features for the repurposed compounds, Cyclica utilized SWITCHx-its data mining technology and DIVEx a platform supporting chemogenomics visualization tools. The outcome of the collaboration is 3 lead repurposed candidates that CWR will further investigate as a potential treatment for IPF.


News Methods Funding Collaborations

Elsevier Supports Findacure to Address Rare Disease Challenge

March 1st 2016, Posted by: Drug Repurposing Portal

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced it is working with Findacure to identify drug repurposing candidates for the rare disease Congenital Hyperinsulinism (CHI). Elsevier R&D Solutions will provide pro bio-informatics expertise and advice, as well as access to published literature through its online tools for a period of three years, to help researchers understand the mechanisms of the disease. Working with Findacure and their collaborators, Elsevier will analyze and interpret data to identify existing generic pharmaceuticals with therapeutic potential for the treatment of CHI.


News Methods Funding Collaborations

Astellas hooks up with NuMedii to continue Drug Repurposing Deal Drive

January 15th 2016, Posted by: Drug Repurposing Portal

Astellas Pharma has signed a drug repurposing deal with NuMedii, CA-based NuMedii has been tasked with identifying new indications for an undisclosed number of Astellas compounds. The move consolidated previously disaggregated repurposing programs in one unit. Last month, Astellas moved to bolster the capabilities of the unit by inking a deal with Biovista, which has developed a tool that uses in silico modeling and literature searches to identify connections between compounds and targets.


News Methods Funding Collaborations

BioXcel and Centrexion Partner to Develop Novel Chronic Pain Therapies

January 11th 2016, Posted by: Drug Repurposing Portal

BioXcel engaged in strategic big data collaboration with Centrexion Therapeutics to develop a portfolio of clinical pain therapeutic assets. The collaboration will utilise BioXcel's first-in-class Big Data Innovation Lab (BDI-Lab) to generate optimal therapeutic value at the intersection of pain biology and differentiated products with a higher probability of clinical and commercial success.


News Methods Funding Collaborations

NuMedii, Inc. Announces New Indications Discovery Collaboration with Astellas

January 11th 2016, Posted by: Drug Repurposing Portal

Astellas collaborates with NuMedii to explore new indications for a number of their compounds. NuMedii will deploy its predictive big data intelligence technology that enables discovery of new uses for marketed drugs as well as shelved development assets across therapeutic areas.


News Methods Funding Collaborations

Roche Links with UK Gov for Ground-breaking PAH Trial

January 6th 2016, Posted by: Drug Repurposing Portal

Under NIHR's Rare Disease Collaboration, Roche and Department of Health have partnered to assess the repositioning potential of an available arthritis biologic tocilizumab; from Roche marketed as RoActemra for the treatment of pulmonary arterial hypertension (PAH). A two-year trial involving 50 patients, led by the Papworth Hospital NHS Foundation Trust and funded by NIHR is aimed to evaluate the effects of tocilizumab in slowing down the disease progression.


News Methods Funding Collaborations

Biovista Inc. Announces Drug Repositioning Collaboration with Astellas Pharma

December 3rd 2015, Posted by: Drug Repurposing Portal

Biovista and Astellas Pharma Inc. have collaborated to identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) technology. It will use the Drug Repurposing and Application Management at Astellas and the large scale systematic drug repositioning technology at Biovista to help patients in need benefit even more from Astellas drugs.


News Methods Funding Collaborations

Cloud Pharmaceuticals, Therametrics hook up for CNS drug discovery drive

October 2nd 2015, Posted by: Drug Repurposing Portal

The Swiss drug discovery company Therametrics teams up with Cloud Pharmaceuticals to use its DDR 2.0 repurposing and repositioning software to find novel targets for a CNS project. Once Therametrics identifies the mode of action of a particular compound, Cloud based on its Quantum Molecular Design Process predicts the binding affinities of the compound in a library and determines their safety and efficacy in silico. Therametrics CRO unit will carry out the clinical research programs further for the qualified list of compounds.


News Methods Funding Collaborations

NuMedii, Inc. Announces Research Collaboration with Allergan To Explore New Treatments For Psoriasis

September 29th 2015, Posted by: Drug Repurposing Portal

The collaboration will use NuMedii's predictive Big Data intelligence platform technology (originally built at Stanford University) that uses network-based algorithms to discover drug-disease connections. NuMedii will provide Allergan with proprietary, de-risked therapeutic candidates for psoriasis that are compatible with the 505(b)2 drug development regulatory pathway.


News Methods Funding Collaborations

Vanderbilt Institute for Clinical & Translational Research and Cures Within Reach to Bolster 'Rediscovery Research'

September 10th 2015, Posted by: Drug Repurposing Portal

The Vanderbilt Institute for Clinical and Translational Research (VICTR) is partnering with a public charity, Cures Within Reach, to encourage 'rediscovery research', the repurposing of already approved medical treatments to other conditions or diseases. The goal is to connect researchers and clinicians to patient groups, the biomedical industry and to potential sources of funding, and ultimately increase the healthcare impact of repurposing research projects.


News Methods Funding Collaborations

Biovista Sponsors Wylder Nation Foundation's Research On Acid Sphingomyelinase Deficiency

September 2nd 2015, Posted by: Drug Repurposing Portal

Biovista, a privately held biotechnology company that finds novel uses for drugs and assesses their benefit/risk profile using mechanism-of-action big data analytics, will use its drug repositioning and pathway analytics capability to support Steven Laffoon and his team at Wylder Nation Foundation in the study of Niemann-Pick Disease Type A (NPA), a rare and fatal Lysosomal Storage Disorder also known as Acid Sphingomyelinase Deficiency (ASMD).


News Methods Funding Collaborations

Elsevier's Pharmapendiumtm Bolsters Ucl's Research In Drug Repurposing And Personalized Medicine

August 24th 2015, Posted by: Drug Repurposing Portal

PharmaPendium is a decision support solution designed to help improve drug development decisions by enabling access to the most comprehensive resource of fully searchable FDA/EMA drug approval documents and associated comparative extracted databases.


News Methods Funding Collaborations

Uniquest And Astrazeneca In Drug Repositioning Open Innovation Collaboration

August 10th 2015, Posted by: Drug Repurposing Portal

AstraZeneca and UniQuest have formed an "open innovation" program, which will focus on drug repositioning and finding new uses for AstraZeneca's previously-studied compounds.


News Methods Funding Collaborations

Former Teva CEO's new gig at Ovid Therapeutics

April 16th 2015, Posted by: Drug Repurposing Portal

Ovid Therapeutics announced a deal with Lundbeck, to acquire selected failed compounds in exchange of milestone payments and royalties. The company plans to work on OV101 (gaboxadol-tested for Insomnia by Merck & Lundbeck) to treat Angelman and Fragile X syndrome.


News Methods Funding Collaborations

Takeda, BioXcel Partner to Repurpose Compounds for Rare Diseases

April 9th 2015, Posted by: Drug Repurposing Portal

After seeing recent success of ixazomib (MLN9708), Takeda Pharmaceutical's US forges collaboration with BioXcel; a big data innovation company to repurpose compounds for rare diseases. BioXcel will use its PharmaGPS TM Orphan Disease Suite and Integrated Center of Xcellence platforms, an integral part of their 'Innovation Lab'.


News Methods Funding Collaborations

CureAccelerator

April 1st 2015, Posted by: Drug Repurposing Portal

The CureAccelerator community is composed of like-minded people who are dedicated to creating effective treatments through repurposing.More than 7,000 diseases have no fully effective treatment, affecting more than 500 million people worldwide. Thousands of existing drugs and devices have the potential to be repurposed to treat patients waiting for a cure. We want to see if they work - and were not the only ones.CureAccelerator, the world's first online, interactive platform dedicated to Repurposing Research.


News Methods Funding Collaborations

UCLB And Cycle Pharmaceuticals Enter Into Partnership To Repurpose Drugs For Liver Diseases

February 27th 2015, Posted by: Drug Repurposing Portal

UCLB entered into a partnership agreement with Cycle Pharmaceuticals to develop existing drugs for new uses in treating liver diseases. UCLB has licensed Intellectual Property from research carried out at UCL (University College London) to Cycle Pharmaceuticals as a part of this transaction. UCLB (UCL Business PLC) is a leading technology transfer company that supports and commercializes research and innovations arising from UCL, one of the UK's top research-led universities.


News Methods Funding Collaborations

Revive Therapeutics Enters Into Research Collaboration with Rettsyndrome Organization

January 15th 2015, Posted by: Drug Repurposing Portal

REV-003 (Tianeptine) will be tested for alternative therapeutic treatment of Rett syndrome in a mouse model and will also undergo testing of a few neurological/behavioral parameters.


News Methods Funding Collaborations

MJFF Highlights Promising Parkinsons Disease Drug Research

August 12th 2014, Posted by: Drug Repurposing Portal

Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program.


News Methods Funding Collaborations

Health Innovation Challenge Fund For Drug Repurposing

July 2nd 2014, Posted by: Drug Repurposing Portal

Wellcome Trust and the Department of Health (UK) have partnered to create "Health Innovation Challenge Fund" to fund the research in areas of special interest, which includes Drug Repurposing.


News Methods Funding Collaborations

UCB, Dermira To Repurpose Arthritis Drug To Treat Psoriasis

June 30th 2014, Posted by: Drug Repurposing Portal

UCB and Dermira to Repurpose Arthritis Drug to Treat Psoriasis. UCB is teaming up with dermatology company Dermira to develop and commercialize the arthritis drug Cimzia (certolizumab pegol), with the aim of making it available to patients with psoriasis.


News Methods Funding Collaborations

Shire Boosts Rare Disease Portfolio With $260M Lumena Deal

May 13th 2014, Posted by: Drug Repurposing Portal

Shire has acquired rare disease-focused Lumena Pharmaceuticals of San Diego for $260m in cash. Lumena is developing repurposed cholesterol-lowering drugs that it licensed from Pfizer and Sanofi to treat cholestatic liver diseases.


News Methods Funding Collaborations

Global Partners Are Taking The "Neglect" Out Of "Neglected Tropical Diseases"

May 5th 2014, Posted by: Drug Repurposing Portal

"United to combat neglected tropical diseases", coaliton of pharmaceutical companies, donor groups, implementing partners, national NTD programs and other supportive partners, received $240 million from Bill Gates, the World Bank and other donors to fight neglected tropical diseases.


News Methods Funding Collaborations

To Spark Cancer Discoveries, Several Big Pharma Companies Are Sharing Idle Clinical Trial Data

April 29th 2014, Posted by: Drug Repurposing Portal

To spark cancer discoveries, a consortium of Big Pharma companies and research organizations are attempting to give that Clinical trial data a second life by making it available to researchers on the new Project Data Sphere platform. It includes nine data sets from AstraZeneca, Bayer, Celgene, Johnson & Johnson, Pfizer, Sanofi and Memorial Sloan Kettering Cancer Center.


News Methods Funding Collaborations

Shionogi Inc Announces Co-Promotion Agreement With Noven Pharmaceuticals For Brisdelle (Paroxetine) Capsules (Shionogi & Co Ltd)

April 21st 2014, Posted by: Drug Repurposing Portal

Shionogi Inc signed an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote Brisdelle, a repurposed drug for hot flashes in women, along with Osphena.


News Methods Funding Collaborations

Promoting Drug Re-Profiling Between Industry And Academia

April 15th 2014, Posted by: Drug Repurposing Portal

Osaka University and AstraZeneca signed a memorandum on joint research on drug re-profiling studies in the area of cardiovascular diseases. AstraZeneca will provide Osaka University with information on non-clinical and clinical trials for specific chemical compounds. Exploiting its know-how, Osaka University will fully examine the information and conduct non-clinical research, in consultation with AstraZeneca, on new applications for cardiovascular diseases.


News Methods Funding Collaborations

Experts Discuss Finding Solutions On Drug Development For Diseases Of Poverty

April 15th 2014, Posted by: Drug Repurposing Portal

Guardian s Global Development Professional Network hosted an interactive online discussion that focused on challenges and solutions for funding drug development for diseases of poverty and drug repurposing was one of the solutions proposed to address this problem.


News Methods Funding Collaborations

Matrix Trial Will Advance Personalized Medicine For Lung Cancers

April 14th 2014, Posted by: Drug Repurposing Portal

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer marking a new era of research into personalized medicines to treat cancer.


News Methods Funding Collaborations

Boehringer Gets Fresh Fda Approval For Pradaxa

April 9th 2014, Posted by: Drug Repurposing Portal

Boehringer Ingelheim's anticoagulant Pradaxa gets fresh FDA approval for recurrent deep vein thrombosis and pulmonary embolism.


News Methods Funding Collaborations

Abatacept May Prevent Kidney Disease Advance In Diabetics

April 9th 2014, Posted by: Drug Repurposing Portal

Paolo Fiorina, of Boston Children's Hospital used Abatacept, currently indicated for Rheumatoid Arthritis, prevented progression of diabetic nephropathy in preclinical studies.


News Methods Funding Collaborations

Liver X Receptor (Lxr) Agonists (Shelved Compounds) Originally Developed For Cardiovascular Diseases And Have Shown To Treat Metastatic Melanoma In Preclinical Models

April 7th 2014, Posted by: Drug Repurposing Portal

Liver X receptor (LXR) agonists (Shelved compounds) originally developed for cardiovascular diseases and have shown to treat metastatic melanoma in preclinical models.


News Methods Funding Collaborations

Partnerships For Drug Repositioning: Lessons From The Ctsa Pharmaceutical Assets Portal

April 4th 2014, Posted by: Drug Repurposing Portal

Seven firms collaborating on this partnership include: AstraZeneca, GlaxoSmithKline, Pfizer, Janssen Research & Development LLC, Lilly, Takeda and UCB are offering up their deprioritised compounds to UK researchers.


News Methods Funding Collaborations

Rebamipide Opc-12759 In The Treatment Of Dry Eye: A Randomized, Double-Masked, Multicenter, Placebo-Controlled Phase Ii Study

April 1st 2014, Posted by: Drug Repurposing Portal

Otsuka Pharmaceuticals and Acucela, Inc repurposed Rebamipide (Gastroprotectant) for dry eye.


News Methods Funding Collaborations

GSK, EMBL-EBI And Wellcome Trust Sanger Harness Big Data And Genomics For Target Validation

March 31st 2014, Posted by: Drug Repurposing Portal

GlaxoSmithKline (GSK), the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute have established a public-private partnership, the Centre for Therapeutic Target Validation (CTTV), which aims to exploit the power of big data and genome sequencing to speed the validation of new drug targets. The new CTTV will address a wide range of human diseases and share its data openly.


News Methods Funding Collaborations

Certara Partners With Thomson Reuters To Expand Data Access Through Its D360 Drug Discovery And Development Platform

March 24th 2014, Posted by: Drug Repurposing Portal

Certara partners with Thomson Reuters to provide its customers with access to Thomson Reuters Cortellis for Informatics life sciences content through its D360 platform.


News Methods Funding Collaborations

Intellimedix Using Biotech To Find Cures For Childhood Diseases

March 17th 2014, Posted by: Drug Repurposing Portal

Intellimedix, a biotech company, is interested in using drug repurposing for development of treatment for Darvet's syndrome and other Neurological disorders through collaborations.


News Methods Funding Collaborations

SOM Biotech Licenses Drug Candidate For Glioblastoma To Argon Pharma

March 10th 2014, Posted by: Drug Repurposing Portal

SOM0777 (Repurposing candidate), developed by SOMBIOTECH (Drug Repurposing company) was licensed to Argon Pharma to treat Multiple glioblastoma.


News Methods Funding Collaborations

Cancer Research Uk Will Repurpose An Astrazeneca Asthma Drug For Kidney Cancer

March 10th 2014, Posted by: Drug Repurposing Portal

Cancer Research UK and Cancer Research Technology the charity s development and commercialization arm have reached an agreement with AstraZeneca to take AZD2098, an experimental drug originally designed for asthma, into a clinical trial to treat kidney cancer.


News Methods Funding Collaborations

Repurposed Candidate Mlr-1023, A First-In-Class Insulin Sensitizer For The Treatment Of Type 2 Diabetes

March 10th 2014, Posted by: Drug Repurposing Portal

Melior Pharmaceuticals, Inc and Bukwang Pharmaceutical Co. Ltd., of South Korea have reached an agreement to develop, manufacture and commercialize its a repurposed candidate MLR-1023, a first-in-class insulin sensitizer for the treatment of type 2 diabetes.


News Methods Funding Collaborations

The Myelin Repair Foundation And Nih Enter Agreement For The Clinical Development Of Mrf-008, A Drug Repurposing Opportunity For Multiple Sclerosis

March 3rd 2014, Posted by: Drug Repurposing Portal

The Myelin Repair Foundation (MRF) has entered a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) to repurpose MRF-008 (FDA approved anti-hypertensive drug), as a potential therapeutic for multiple sclerosis (MS).


News Methods Funding Collaborations

SOM3355 (A Repurposed Candidate), Potent Inhibitor Of Vesicular Monamine Transporter-2 Has Been Shown To Be Beneficial For The Treatment Of Huntington'S Disease In Pre-Clinical Studies

March 3rd 2014, Posted by: Drug Repurposing Portal

SOM3355 (a repurposed candidate), potent inhibitor of Vesicular monamine transporter-2 has been shown to be beneficial for the treatment of Huntington's disease in pre-clinical studies.


News Methods Funding Collaborations

The Drug-Discovery Platform From The Barcelona Science Park Licensed Som Biotech Up To 219 Reprofiling Drugs To Be Developed By The Company And Lead To Development Of 5 Promising Potential Drugs In Pre-Clinical Studies

March 3rd 2014, Posted by: Drug Repurposing Portal

The Drug-Discovery Platform from the Barcelona Science Park licensed SOM Biotech up to 219 reprofiling drugs to be developed by the company and lead to development of 5 promising potential drugs in pre-clinical studies.


News Methods Funding Collaborations

Collaboration With Medicines For Malaria Venture Through Global Health Innovative Technology Fund

February 24th 2014, Posted by: Drug Repurposing Portal

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has entered into agreements with Medicines for Malaria Venture ("MMV") to study DSM265 and ELQ300, two anti-malarial compounds, with the support of the Global Health Innovative Technology Fund ("GHIT Fund").


News Methods Funding Collaborations

SOM Biotech Starts Collaborations With Aagami Inc

February 24th 2014, Posted by: Drug Repurposing Portal

SOM Biotech (Drug Repurposing company) reaches an agreement with Aagami Inc. to start collaborations with Indian pharmaceutical companies interested in drug reprofiling.


News Methods Funding Collaborations

Malaria: Medicines For Malaria Venture Funded

February 24th 2014, Posted by: Drug Repurposing Portal

Medicines for Malaria Venture (MMV) funded Drug Discovery Unit at University of Dundee to develop potential anti-malaria clinical candidates.


News Methods Funding Collaborations

Transatlantic Partnership Pools Us$3 Million For Alzheimer'S Drug Discovery

January 28th 2014, Posted by: Drug Repurposing Portal

A transatlantic partnership between US-based Alzheimer s Drug Discovery Foundation (ADDF) and UK s Alzheimer s Society is putting US$3 million into research projects aimed at repurposing existing drugs as potential therapies for Alzheimer s disease and related dementias.


News Methods Funding Collaborations

twoXAR Collaborates with Researchers at Mount Sinai to Advance New Medicines for Diabetic Nephropathy

May 12th 0012, Posted by: Drug Repurposing Portal

twoXAR, Inc., a company dedicated to improving health through computation, today announced its collaboration with researchers from the Icahn School of Medicine at Mount Sinai to further validate computational approaches in early-stage drug discovery. Repurposing candidates were identified using twoXAR's computational methodology, and cross-examined against candidates identified using methods developed in the Maayan Lab. Both technologies leverage machine learning and large biomedical datasets to make unanticipated disease-to-candidate matches. twoXAR has developed patent pending algorithms that enable it to find unanticipated associations between disease and drug candidates orders of magnitudes faster than wet lab based approaches. The platform is disease agnostic and has been tested on more than 55 conditions to date in therapeutic areas including autoimmune, oncologic, and neurologic disorders.


News Methods Funding Collaborations
Load More